Cost-effectiveness analysis of pulse oximetry screening for critical congenital heart defects following homebirth and early discharge

Pulse oximetry (PO) screening is used to screen newborns for critical congenital heart defects (CCHD). Analyses performed in hospital settings suggest that PO screening is cost-effective. We assessed the costs and cost-effectiveness of PO screening in the Dutch perinatal care setting, with home births and early postnatal discharge, compared to a situation without PO screening. Data from a prospective accuracy study with 23,959 infants in the Netherlands were combined with a time and motion study and supplemented data. Costs and effects of the situations with and without PO screening were compared for a cohort of 100,000 newborns. Mean screening time per newborn was 4.9min per measurement and 3.8min for informing parents. The additional costs of screening were in total Euro14.71 per screened newborn (Euro11.00 personnel, Euro3.71 equipment costs). Total additional costs of screening and referral were Euro1,670,000 per 100,000 infants. This resulted in an incremental cost-effectiveness ratio of Euro139,000 per additional newborn with CCHD detected with PO, when compared to a situation without PO screening. A willingness-to-pay threshold of Euro20,000 per gained QALY for screening in the Netherlands makes the screening likely to be cost-effective.Conclusion: PO screening in the Dutch care setting is likely to be cost-effective.